The pharmaceutical industry has been slow to adopt a business practice that is faster, safer, and more efficient than its current way of operating; that the FDA has been encouraging the industry to implement more widely for years; and that has been used effectively in other industries for decades. I’m talking about continuous manufacturing.
Continuous manufacturing produces a drug product from start to finish through a nonstop, integrated assembly. In contrast, most of the pharmaceutical industry currently uses batch manufacturing, which involves producing a finished drug product through multiple distinct steps in series.
As a pioneer in the continuous manufacturing of pharmaceuticals, I continue to be surprised by the slow pace at which pharma has embraced this innovation.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect